Celanese Q3 sales rise 6%
CE•CE•CE•CE•Celanese's third-quarter sales rose 6% year over year to $2.56 billion, missing the $2.62 billion consensus, while adjusted EPS of $1.65 beat estimates. The company raised its 2026 adjusted EPS outlook to $6.00-$6.25 and free cash flow forecast to $750 million-$800 million.
Celanese reported third-quarter net sales of $2.56 billion, up 6% year over year and below analysts' $2.62 billion consensus estimate. Adjusted EPS was $1.65, above the $1.56 consensus, and net earnings were $78 million.
The company raised its full-year 2026 adjusted EPS outlook to $6.00-$6.25 and increased its free cash flow forecast to $750 million-$800 million. It expects year-end seasonal moderation across both businesses in the fourth quarter. Growth in medical and electronics applications supported product mix and earnings in Engineered Materials, while Acetyl Chain pricing and incremental spot opportunities offset modest demand softness.
